The promise of placenta-on-a-chip technology

The nascent technology could be a game-changer for studies on pregnancy, an understudied area due to practical and ethical reasons.

June 13, 2024 Check out STAT+

Sponsored By

KC McGinnis for STAT With placenta-on-a-chip, researchers hope to gauge how drugs and toxins impact pregnancy The nascent technology could be a game-changer for studies on pregnancy, an understudied area due to practical and ethical reasons. By Deborah Balthazar Supreme Court unanimously rejects challenge to mailed abortion pills The judges unanimously rejected a challenge to an FDA decision to expand access to abortion pills by mail. By Sarah Owermohle Global health leader critiques 'ineptitude' of U.S. response to bird flu outbreak among cows Seth Berkley, former CEO of Gavi, the Vaccine Alliance, said it's been "shocking to watch the ineptitude," and he fears lessons of Covid have gone unheeded. By Andrew Joseph Evan Vucci/AP Biden and Trump are fighting to claim credit for $35 insulin. It was actually a pharma giant's idea The pharma giant Eli Lilly first proposed $35 insulin for Medicare patients, an idea later adopted by both Biden and Trump. By Rachel Cohrs Zhang STAT+ | Europe is set to shake up the way it assesses new medicines. Gene therapy makers are worried A wonky policy shift in the arcane world of "health technology assessments" has drugmakers big and small racing to adapt. By Andrew Joseph STAT+ | Telehealth startup Done's top leadership arrested on fraud charges Done's top leadership has been arrested on charges of fraud over an alleged "$100 million scheme" to provide easy access to Adderall. By Mohana Ravindranath and Katie Palmer MARTIN BERNETTI/AFP via Getty Images Opinion: What happened to obesity after Chile slew Tony the Tiger? Chile's effort to halt the rise of obesity with dramatic food package warnings sounded like a solution. But it didn't work. By Paul von Hippel STAT+ | Will Geron be acquired? The long-short view This week in biotechnology: Adam Feuerstein's subscriber-only newsletter digs into Geron and Candel Therapeutics. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser